"Biotech is all about innovation, and we forgot that."

– Kleanthis Xanthopoulos, president and CEO of microRNA company Regulus Therapeutics Inc. on the challenges facing the drug development industry

"A quick note to the FDA: Isn't it finally time to make complete response letters public?"

– Rodman & Renshaw analyst Simos Simeonidis in a research note on MannKind Corp.'s CRL for inhaled insulin Afrezza

"Otherwise, you're an army of one charging up a hill."

– Steve Worland, CEO of Anadys Pharmaceuticals Inc., on the importance of working proactively with investors and shareholders